The company, which launched in 2019, raised $41 million in three fund raisers.
The company is headed by CEO Dr. Ravish Sachar, who signed the SEC filing. It is headquartered in Raleigh.
The company was “built on the premise of adding safety to endovascular procedures without compromising performance,” its website reads. Its technology platform “embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes,” according to a company statement.
In November 2022 Contego said it had completed enrollment in a Phase 2 clinical trial “designed to evaluate the safety and effectiveness of the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is designed to treat clinically significant carotid artery stenosis while improving procedural safety through the integration of the stent, balloon and an embolic filter all in a single device.”